MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.

MannKind (MNKD) announced six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder in children and adolescents. MannKind ...

An FDA committee has given an overwhelming recommendation to new inhaled insulin treatment Afrezza. MannKind Corporation has spent years and many millions of dollars in developing the novel ...

Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes ...

The U.S. Food and Drug Administration has approved inhalable insulin to help patients control their blood sugar levels. ManKind Corporation's Afrezza is a fast-acting form of insulin intended for ...